Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Immediate and Long-Term Results of Drug-Eluting Stents in Mammary Artery Grafts.

Lozano I, Serrador A, Lopez-Palop R, Lasa G, Moreu J, Pinar E, de Prado AP, Alfonso F, Jimenez Navarro M, Quero MF, Pineda J, Martin Moreiras J, Garcia San Roman K, Lopez Minguez JR, Suarez Cuervo A, Gutierrez A, Hernandez F, Baz JA, Benedicto A, Rumoroso JR, Gomez-Hospital JA, Serra V, de la Torre JM, Ruiz-Quevedo V, Botas J, Fernandez JA, Sanchez-Recalde A.

Am J Cardiol. 2015 Dec 1;116(11):1695-9. doi: 10.1016/j.amjcard.2015.08.040.

PMID:
26433270
2.

Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial.

von Birgelen C, Sen H, Lam MK, Danse PW, Jessurun GA, Hautvast RW, van Houwelingen GK, Schramm AR, Gin RM, Louwerenburg JW, de Man FH, Stoel MG, Löwik MM, Linssen GC, Saïd SA, Nienhuis MB, Verhorst PM, Basalus MW, Doggen CJ, Tandjung K.

Lancet. 2014 Feb 1;383(9915):413-23. doi: 10.1016/S0140-6736(13)62037-1. Erratum in: Lancet. 2014 Feb 1;383(9915):412.

PMID:
24183564
3.

4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention).

Taniwaki M, Stefanini GG, Silber S, Richardt G, Vranckx P, Serruys PW, Buszman PE, Kelbaek H, Windecker S; RESOLUTE All-Comers Investigators..

J Am Coll Cardiol. 2014 Apr 29;63(16):1617-25. doi: 10.1016/j.jacc.2013.12.036.

4.

Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials.

Sabaté M, Räber L, Heg D, Brugaletta S, Kelbaek H, Cequier A, Ostojic M, Iñiguez A, Tüller D, Serra A, Baumbach A, von Birgelen C, Hernandez-Antolin R, Roffi M, Mainar V, Valgimigli M, Serruys PW, Jüni P, Windecker S.

JACC Cardiovasc Interv. 2014 Jan;7(1):55-63. doi: 10.1016/j.jcin.2013.07.012.

5.

Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial.

Di Lorenzo E, Sauro R, Varricchio A, Carbone G, Cortese G, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G, De Luca G.

Circulation. 2009 Sep 15;120(11):964-72. doi: 10.1161/CIRCULATIONAHA.108.830372. Retraction in: Circulation. 2010 Mar 2;121(8):e228.

6.

Comparison of First- and Second-Generation Drug-Eluting Stents in an All-Comer Population of Patients with Diabetes Mellitus (from Katowice-Zabrze Registry).

Kawecki D, Morawiec B, Dola J, Wańha W, Smolka G, Pluta A, Marcinkiewicz K, Ochała A, Nowalany-Kozielska E, Wojakowski W.

Med Sci Monit. 2015 Oct 27;21:3261-9.

7.

Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study.

Simsek C, Räber L, Magro M, Boersma E, Onuma Y, Stefanini GG, Zanchin T, Kalesan B, Wenaweser P, Jüni P, van Geuns RJ, van Domburg RT, Windecker S, Serruys PW.

Int J Cardiol. 2013 Dec 5;170(1):36-42. doi: 10.1016/j.ijcard.2013.10.006.

PMID:
24196314
8.

Revascularization in severe left ventricular dysfunction: outcome comparison of drug-eluting stent implantation versus coronary artery by-pass grafting.

Gioia G, Matthai W, Gillin K, Dralle J, Benassi A, Gioia MF, White J.

Catheter Cardiovasc Interv. 2007 Jul 1;70(1):26-33.

PMID:
17585381
9.

Long-term clinical outcome of rotational atherectomy followed by drug-eluting stent implantation in complex calcified coronary lesions.

Abdel-Wahab M, Baev R, Dieker P, Kassner G, Khattab AA, Toelg R, Sulimov D, Geist V, Richardt G.

Catheter Cardiovasc Interv. 2013 Feb;81(2):285-91. doi: 10.1002/ccd.24367.

PMID:
22431433
10.

Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).

Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS Jr, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, Stone GW.

JACC Cardiovasc Interv. 2013 Sep;6(9):914-22. doi: 10.1016/j.jcin.2013.05.005.

11.

Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes.

Kaul U, Bangalore S, Seth A, Arambam P, Abhaichand RK, Patel TM, Banker D, Abhyankar A, Mullasari AS, Shah S, Jain R, Kumar PR, Bahuleyan CG; TUXEDO–India Investigators..

N Engl J Med. 2015 Oct 29;373(18):1709-19. doi: 10.1056/NEJMoa1510188. Erratum in: N Engl J Med. 2016 Jul 28;375(4):398. Abhaychand, Rajpal K [Corrected to Abhaichand, Rajpal K].

12.

Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II).

Sen H, Lam MK, Löwik MM, Danse PW, Jessurun GA, van Houwelingen KG, Anthonio RL, Tjon Joe Gin RM, Hautvast RW, Louwerenburg JH, de Man FH, Stoel MG, van der Heijden LC, Linssen GC, IJzerman MJ, Tandjung K, Doggen CJ, von Birgelen C.

JACC Cardiovasc Interv. 2015 Jun;8(7):889-99. doi: 10.1016/j.jcin.2015.01.033.

13.

A preliminary experience report: Drug-eluting stents versus coronary artery bypass surgery in patients with a single lesion in the proximal left anterior descending artery suffering from diabetes mellitus and chronic stable angina.

Toutouzas K, Patsa C, Vaina S, Tsiamis E, Vavuranakis M, Stefanadi E, Spanos A, Iliopoulos D, Panagiotou M, Chlorogiannis I, Pattakos E, Stefanadis C.

Hellenic J Cardiol. 2008 Mar-Apr;49(2):65-71.

14.

Impact of diabetes on the benefits from everolimus-eluting stent as compared to first-generation drug-eluting stent in patients with ST elevation myocardial infarction.

De Luca G, Sauro R, Capasso M, Lanzillo T, Manganelli F, Carbone G, Lanni F, Pagliuca MR, Palmieri V, Serino V, Rosato G, Suryapranata H, Di Lorenzo E.

Diab Vasc Dis Res. 2015 Sep;12(5):306-14. doi: 10.1177/1479164115592252.

PMID:
26150193
17.

Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis.

Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Valgimigli M, Frati G, Kedhi E, Smits PC, Kaiser C, Genereux P, Galatius S, Kirtane AJ, Stone GW.

J Am Coll Cardiol. 2013 Aug 6;62(6):496-504. doi: 10.1016/j.jacc.2013.05.022.

18.

Percutaneous coronary intervention with second-generation paclitaxel-eluting stents versus everolimus-eluting stents in United States contemporary practice (REWARDS TLX Trial).

Waksman R, Ghali M, Goodroe R, Ryan T, Turco M, Ring M, McGarry T, Dobies D, Shammas N, Steinberg DH, Swymelar S, Kaneshige K, Torguson R.

Am J Cardiol. 2012 Oct 15;110(8):1119-24. doi: 10.1016/j.amjcard.2012.05.050.

PMID:
22762711
19.

Three-year clinical outcome after treatment of chronic total occlusions with second-generation drug-eluting stents in the TWENTE trial.

van Houwelingen KG, Sen H, Lam MK, Tandjung K, Löwik MM, de Man FH, Louwerenburg JH, Stoel MG, Hartmann M, Linssen GC, Doggen CJ, von Birgelen C.

Catheter Cardiovasc Interv. 2015 Feb 15;85(3):E76-82. doi: 10.1002/ccd.25713.

PMID:
25339110
Items per page

Supplemental Content

Support Center